Allergan is paying a stunning 500% premium to buy a clinical-stage biotech
September 20, 2016 at 14:27 PM EDT
The usual premium on a company with no approved drugs is closer to 50% to 100%, says RBC.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.